A practical reference on actin-binding motif: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-25. Anything still debated is marked as such rather than presented as settled.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
== Athletic career == Maroon has competed in 8 Ironman Triathlons (Hawaii – 1993, 2003, 2008, 2010, 2013; Canada – 1995; New Zealand – 1997; Germany – 2000) and is to this day an active triathlon athlete. Dr. Maroon was inducted into the Lou Holtz Upper Ohio Valley Hall of Fame in 1999, the Western Chapter of the Pennsylvania Sports Hall of Fame in 2009 and in 2010 also to the National Fitness Hall of Fame in Chicago. For 2016, in the global ranking of Ironman athletes, Maroon ranks in 4th place in his age group. In 2022, Maroon placed second in the National Senior Games for his age group and placed first in the Chicago Triathlon for his age group.
Pauling–Corey–Branson α-helix (from the names of three scientists who described its structure) 3.613-helix because there are 3.6 amino acids in one ring, with 13 atoms being involved in the ring formed by the hydrogen bond (starting with amidic hydrogen and ending with carbonyl oxygen)
Ronald Charles Dean (August 15, 1938 – October 5, 2025) was an American film and television actor. He appeared in films including Risky Business, The Breakfast Club, Cocktail, The Babe, The Fugitive, Rudy, The Client, and The Dark Knight. He is known for having often played detectives and other law-enforcement characters, most notably as Det. Marion Zeke Crumb in the fantasy comedy-drama television series Early Edition.
Kellogg (1860–1951) worked for him for many years until, in 1906, he broke away, bought the rights to Cornflakes, and set up the Kellogg Toasted Corn Flake Company. William Kellogg discarded the health food concept, opting for heavy advertising and commercial taste appeal. Later, his signature on every package became the company trademark.
=== Workflow === Long-wavelength UV and SDA reagents are first supplied to living cells to crosslink protein residues with RNA by forming amide bonds between amine groups of lysine (or arginine) residues and succinimidyl esters. Next, cells containing crosslinked RNPs are lysed and the RNA-bound proteins are digested into peptide adducts. MaP reverse transcription is then performed to label the protein-RNA binding sites through peptide adduct-induced mutations. Sequencing of the mutation-containing cDNA product will reveal the mutation sites (or RNP-MaP sites) and the correlations between the RNP-MaP sites are computationally determined using 3-nucleotide windows.
Sources: en.wikipedia.org
Moore and another Liverpool biochemist, Edward Whitney, founded the Biochemical Journal in 1906, one year after the creation of the US-based Journal of Biological Chemistry in 1905. Both journals still exist. Moore served as the first Biochemical Journal editor with the journal initially being published by the Liverpool University Press, the 3rd oldest University Press in England. Moore was concerned with the high mortality for the United Kingdom of pulmonary tuberculosis (TB), which he called the ‘Great White Plague', concluding that with 'the foundation of a new National Health Service and the provision of segregation for infectious cases in sanatoria, the disease could be eradicated'. Other holders of the Johnston Chair include RA Morton, FRS HH Rees, the late Trevour Goodwin FRS and the current Head of Department PA Eyers The Liverpool-originated Biochemical Journal was acquired by the London-based Biochemical Club (later renamed the Biochemical Society in 1911.
=== Taxpayer Bill of Rights === In 1998, Kennedy advocated for the passage of Act 136, a bill that established a Taxpayer's Bill of Rights. The bill guaranteed that taxpayers would be treated with respect, have access to instructions "written in plain English", receive quick responses to questions from the Department of Revenue, and receive notice if they were in violation of the tax policy, among other things. Kennedy used the Taxpayer's Bill of Rights as a foundation to advocate for more tax code changes. In 1999, he proposed tax code changes that would protect people from prosecution for tax crimes that their spouses committed without their knowledge. He also proposed "Fair Interest" policies that halted the accrual of interest on tax liabilities held by people whom the Department of Revenue did not notify were in violation of state tax policy. Kennedy said the efforts helped ensure Louisiana residents had a tax system that was as "fair, easy, and convenient as possible", adding, "We look upon taxpayers as our customers...not our enemies."
A tactic in which security forces pose as 'pseudo' insurgents to gather intelligence was developed prior to the Rhodesian Bush War, and had also been used by police forces. Pseudo operations involve security force personnel being trained to closely imitate insurgents. Teams of these personnel then enter regions where insurgents are active and portray themselves as insurgents. After establishing credibility, the team collects intelligence on actual insurgents and their sources of support. These tactics can be most necessary in regions where the insurgents have eliminated the government's sources of intelligence, as was the case in north-eastern Rhodesia in 1973. In general, 'pseudo' teams undertake only intelligence collection work, and do not attack insurgents themselves. 'Pseudo' tactics are generally most effective when the teams include former insurgents who have been 'turned' to side with the government. The effectiveness of these tactics is partially dependent on their use not becoming known, as this will lead to insurgents improving their security processes. Internationally, there has also been a risk of pseudo units breaking the law. If local civilians learn that the security forces are posing as insurgents and using this as cover to break the law, the tactics can be counter-productive as they will erode support for the government. The British authorities used pseudo tactics during the Malayan Emergency, with this coming to the attention of the Rhodesians who took part in that conflict.
Analogous to the behavior of other chalcogens, selenium forms hydrogen selenide, H2Se. It is a strongly odiferous, toxic, and colorless gas. It is more acidic than H2S. In solution it ionizes to HSe−. The selenide dianion Se2− forms a variety of compounds, including the minerals from which selenium is obtained commercially. Illustrative selenides include mercury selenide (HgSe), lead selenide (PbSe), zinc selenide (ZnSe), and copper indium gallium diselenide (Cu(Ga,In)Se2). These materials are semiconductors. With highly electropositive metals, such as aluminium, these selenides are prone to hydrolysis, which may be described by this idealized equation:
==== Distribution ==== The volume of distribution of THC is large and is approximately 10 L/kg (range 4–14 L/kg), which is due to its high lipid solubility. The plasma protein binding of THC and its metabolites is approximately 95 to 99%, with THC bound mainly to lipoproteins and to a lesser extent albumin. THC is rapidly distributed into well-vascularized organs such as lung, heart, brain, and liver, and is subsequently equilibrated into less vascularized tissue. It is extensively distributed into and sequestered by fat tissue due to its high lipid solubility, from which it is slowly released. THC is able to cross the placenta and is excreted in human breast milk.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.